Abstract
A six month, double blind, crossover controlled trial of bezafibrate was conducted in 14 children with familial hypercholesterolaemia all of whom had a strong family history of early coronary heart disease. The bezafibrate was given twice daily in a dose of 10 to 20 mg/kg/day. The mean plasma total cholesterol concentration on bezafibrate was 22% lower than during the period on placebo and there was a moderate rise in high density lipoprotein cholesterol. Bezafibrate may be a useful adjunct to treatment in these children.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Leonard J. V., Whitelaw A. G., Wolff O. H., Lloyd J. K., Slack J. Diagnosing familial hypercholesterolaemia in childhood by measuring serum cholesterol. Br Med J. 1977 Jun 18;1(6076):1566–1568. doi: 10.1136/bmj.1.6076.1566. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Mordasini R., Riesen W., Oster P., Keller M., Middelhoff G., Lang P. D. Reduced LDL- and increased HDL-apoproteins in patients with hypercholesterolaemia under treatment with bezafibrate. Atherosclerosis. 1981 Oct;40(2):153–158. doi: 10.1016/0021-9150(81)90033-2. [DOI] [PubMed] [Google Scholar]
- West R. J., Lloyd J. K. Hypercholesterolemia in childhood. Adv Pediatr. 1979;26:1–34. [PubMed] [Google Scholar]
- West R. J., Lloyd J. K., Leonard J. V. Long-term follow-up of children with familial hypercholesterolaemia treated with cholestyramine. Lancet. 1980 Oct 25;2(8200):873–875. doi: 10.1016/s0140-6736(80)92044-9. [DOI] [PubMed] [Google Scholar]